CRSPCRISPR Therapeutics AG

$54.74

The financials

CRISPR Therapeutics AG by the numbers

Its largest product in Jun 2026 was Collaboration at $10M, 98% of the disclosed total, well ahead of Grant at 1.8%.

Revenue by product, Jun 2026, as reported to the SEC
ProductRevenueShare
Collaboration$10M98%
Grant$181K1.8%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Jun 2026Total $10.2M (+598%)
Grant grew -80% year on year
  • Collaboration$10.0MQoQ +900%year on year -
  • Grant$181.0KQoQ -60%year on year -80%
Segment sum = 100% of reported consolidated revenue · Latest source: 10-Q filed 2026-08-03, SEC EDGAR